Table 3.

Effects of cannabinoids on inflammasomes.

Cannabinoids	Inflammasome	Effect observed	In vitro and/or in vivo model	Possible mechanism of action	Ref
CBD	NLRP3	Inhibition of NLRP3 mRNA and protein	Human gingival mesenchymal stem cells	Possibly via inhibiting NF-κB-induced priming	(194)
	NLRP3	Protection of liver from non-alcoholic steatohepatitis	High-fat, high-cholesterol (HFC) diet C57BL/6J mice and RAW264.7 murine cells	Inhibition of NF-κB- mediated priming step	(195)
	NLRP3	Cytoprotection against UV rays via inhibition of NLRP3	Human keratinocytes treated with UV-A and UV-B rays	Reduction of NF-κB levels by inhibiting Nrf-2 and NF-κB interaction	(208)
	NLRP3	Anti-inflammatory action via impeding NLRP3	LPS-nigericin-stimulated human THP-1 monocytes	Decreased potassium efflux by modulating P2X7 receptors	(209)
JD5037	NLRP3	Normoglycemia and improved type-2 diabetes profile by NLRP3 inhibition	Zucker diabetic fatty (ZDF) rats	Peripheral CB1 receptor inverse agonism	(201)
HU‐308	NLRP3	The anti-inflammatory effect in human multiple sclerosis model via NLRP3 blockade	Mouse model of experimental autoimmune encephalomyelitis	Selective CB2 receptor activation promotes autophagy leading to inhibition of NLRP3	(202)
AJ5012	NLRP3	Suppression of adipose tissue inflammation by NLRP3 inhibition	Diet-induced obese (DIO) and leptin receptor–deficient C57BL/6J mice	Peripheral CB1 receptor antagonism	(203)
JWH-133	NLRP3	Anti-inflammatory action via decreased priming and activation of NLRP3	Primary murine cardiomyocytes treated with oxygen-glucose deprivation	Selective CB2 receptor agonism	(205)
AM1241	NLRP3	Anti-inflammatory potential via NLRP3 assembly inhibition	Rat macrophagic NR8383 cells treated with complete Freund’s adjuvant (CFA)	Selective CB2 agonism	(206)
HU-308	NLRP3	Anti-inflammatory potential via NLRP3 inhibition	LPS/DSS-induced in vitro colitis model of freshly isolated murine macrophages	Selective CB2 receptor activation promotes autophagy leading to inhibition of NLRP3	(207)